Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
BACKGROUND B cells play a central role in the pathogenesis of systemic lupus erythematosus (SLE) and are a therapeutic target. We therefore assessed the efficacy and safety of obinutuzumab β, a glycoengineered type II anti-CD20 monoclonal antibody, in patients with active SLE. METHODS In this multicentre, randomised,...